Paroxysmal tonic upgaze: A heterogeneous clinical condition responsive to carbonic anhydrase inhibition. (March 2020)

• Record Type: Journal Article
• Authors: Quade, Annegret; Thiel, Anne; Kurth, Ingo; Holtgrewe, Manuel; Elbracht, Miriam; Beule, Dieter; Eggermann, Katja; Scholl, Ute I.; Häusler, Martin
• Is Part Of: European journal of paediatric neurology. Volume 25(2020)
• Page Start: 181
• Page End: 186
• Publication Date: 2020-03
• Subjects: Paroxysmal tonic upgaze -- Episodic ataxia -- SIM1 -- Acetazolamide -- Sultiame -- CACNA1A; Pediatric neurology -- Periodicals; Nervous System Diseases -- Periodicals; Child -- Periodicals; Infant -- Periodicals; Neurologie pédiatrique -- Périodiques; Pediatric neurology; Electronic journals; Periodicals; Electronic journals; 618.928
• DOI: 10.1016/j.ejpn.2019.11.002
• Languages: English
• ISSNs: 1090-3798

Abstract

Abstract: Background: Paroxysmal tonic upgaze (PTU), defined as an involuntary upward movement of the eyes, has been considered as a benign phenomenon but may also be associated with ataxia and developmental delay. Methods: We report eight children with PTU; six of them also exhibiting symptoms of ataxia and/or developmental delay. Treatment with carbonic anhydrase inhibition was offered to children with persisting and/or severe forms. Results: Whole-exome sequencing and genome-wide array analysis (n = 7) did not reveal mutations in the three known genes associated with PTU (CACNA1A, GRID2, SEPSECS), whereas by MLPA a heterozygous deletion of exon 31 of the CACNA1A gene could be detected in one patient, her mother and two further family members. Further exome and array analysis showed no recurrent variants in potentially novel PTU-related genes in more than one patient. A de novo variant at a highly conserved position in the SIM1 gene was detected in one patient, for which a pathogenic effect could be speculated. Carbonic anhydrase inhibition was started in five children and proved at least partially effective in all of them. Conclusion: Irrespective of the clinical background and the molecular basic mechanism of PTU, therapeutic carbonic anhydrase inhibition was effective in all five children (acetazolamide, n = 3; sultiame, n = 2) who received this treatment. Highlights: PTU associated with further symptoms such as developmental delay or ataxia seems to be more persistent. PTU can be associated with genetic mutations in the CACNA1A gene but can also be of multifactorial genesis. Treatment with carbonic anhydrase inhibitors should be considered in all children with persisting or severe forms of PTU.